5 Key Takeaways

• 1

  Semifluorinated alkanes (SFAs) are promising new topical medications for chronic dry eye, offering unique properties beneficial to the ocular surface.

• 2

  F6H8 increases tear breakup time and lipid layer thickness, forming a protective layer that decreases tear evaporation and improves ocular surface homeostasis.

• 3

  Clinical trials show F6H8 significantly improves dry eye symptoms compared to saline controls and is well tolerated without notable side effects.

• 4

  F4H5 enhances the bioavailability of cyclosporine, improving dry eye signs and symptoms with an earlier onset of action compared to other formulations.

• 5

  Both F6H8 and F4H5 are FDA approved and may lead to more ophthalmic medications utilizing SFA compounds for dry eye treatment.